Kodiak Sciences Inc. announced that the first patient has been treated in the Phase 1 study of KSI-501, an investigational bispecific antibody biopolymer conjugate targeting both VEGF and IL-6. KSI-501 is the second product candidate built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform to enter the clinic. The Phase 1 study of KSI-501 is being conducted in the USA as an open-label, multiple ascending dose study and initially is enrolling patients with diabetic macular edema (DME). The primary objectives of the Phase 1 study are to evaluate ocular and systemic safety and to establish a maximum tolerated dose.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.61 USD | -2.97% |
|
-6.45% | -14.14% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.14% | 137M | |
+14.84% | 121B | |
+18.31% | 112B | |
+2.94% | 22.72B | |
-18.26% | 20.82B | |
-18.47% | 16.66B | |
-42.36% | 16.36B | |
-14.23% | 16.19B | |
-0.68% | 13.17B | |
+21.87% | 11.11B |
- Stock Market
- Equities
- KOD Stock
- News Kodiak Sciences Inc.
- Kodiak Sciences Inc. Expands Development Pipeline with Treatment of First Patient in Phase 1 Clinical Study of KSI-501, an Investigational Bispecific Antibody Biopolymer Conjugate for Retinal Diseases